Cftr Trikafta denied as duplicate or overlapping therapy by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for cftr trikafta are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denied Trikafta as Duplicate Therapy — and Why That Is Contestable

A duplicate-therapy denial from UnitedHealthcare (UHC) signals that the plan's system detected another claim for a medication it classifies in the same therapeutic category — typically another CFTR modulator — and automatically blocked the new claim. For Trikafta (elexacaftor/tezacaftor/ivacaftor), this denial type is frequently a claims-processing artifact rather than a clinical judgment, because Trikafta is a three-drug fixed-dose combination with a distinct FDA-approved indication profile compared with earlier modulators.

## Why This Denial Happens

Automated duplicate-therapy edits compare drug class codes, not molecular targets or mutation-specific indications. If a patient was recently on a prior CFTR modulator — or if a transition prescription overlapped by even one day — the system flags both claims. The denial does not reflect a clinical determination that the two drugs serve identical purposes for this patient.

## Your Federal Appeal Rights

• Internal appeal: Under ERISA §503 or applicable state law, request a formal internal appeal. Ask UHC to provide the specific duplicate-therapy rule invoked and the drug it identified as the duplicate.
• External review (ACA §2719): If the internal appeal is denied, you may request independent external review within approximately four months of the final denial notice. The external reviewer will assess whether the two therapies are genuinely interchangeable for this patient's mutation profile and clinical status.
• Expedited review: If a supply gap would seriously harm health, request expedited processing (72-hour decision requirement).

## Documentation to Gather

1. Identification of the alleged duplicate — request in writing which drug UHC identified as the duplicate and the date range of overlap. 2. Prescription transition records — documentation showing that any prior modulator was discontinued before or concurrent with Trikafta initiation, with no intentional overlap. 3. Mutation-specific indication — chart notes and genetic testing showing the CFTR mutation(s) and a prescriber statement confirming that Trikafta's FDA-approved indication is not duplicative of the prior drug for this patient. 4. Prescriber medical-necessity letter — explains that Trikafta is not a therapeutic substitute for the prior drug but rather the clinically appropriate agent for this patient's specific mutation class. 5. Pharmacy records — claims history showing that the prior drug has been stopped.

## Criteria-Mapping Structure

Obtain UHC's published duplicate-therapy policy and the FDA prescribing labels for both Trikafta and the drug identified as the duplicate. Then construct a point-by-point comparison:

| UHC Duplicate-Therapy Criterion | Your Evidence | |---|---| | Definition of "duplicate" under the policy | Demonstration that the two drugs have distinct mutation-class indications per their FDA labels | | Overlap date range | Pharmacy records showing no active overlap | | Clinical interchangeability standard | Prescriber letter citing non-identical mechanism and indication |

Clearly resolving the factual basis of the duplication finding — and showing it was a processing artifact — is typically sufficient to achieve reversal at internal appeal.